IFF Q4 2021 Earnings Report
Key Takeaways
IFF reported strong fourth quarter results with a 139% increase in net sales to $3.03 billion, driven by the merger with Nutrition & Biosciences. Adjusted EPS excluding amortization was $1.10 per diluted share. The company is focused on pricing execution and cost discipline to improve operational performance amid inflationary pressures.
Reported net sales for the fourth quarter were $3.03 billion, an increase of 139% compared to the prior year period.
Adjusted operating EBITDA for the fourth quarter was $529 million, an increase of $292 million, or 123%, from $237 million in 2020.
Reported earnings per share (EPS) for the fourth quarter was $0.35.
Adjusted EPS excluding amortization was $1.10 per diluted share.
IFF
IFF
IFF Revenue by Segment
Forward Guidance
The Company expects full year 2022 sales to be approximately $12.3 billion to $12.7 billion, with an expected full year 2022 adjusted operating EBITDA of approximately $2.5 billion to $2.6 billion.